Biologics and cardiovascular events in inflammatory arthritis: a prospective national cohort study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1478-6362
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Biologics and cardiovascular events in inflammatory arthritis: a prospective national cohort study ; volume:20 ; number:1 ; day:7 ; month:8 ; year:2018 ; pages:1-9 ; date:12.2018
Arthritis Research & Therapy ; 20, Heft 1 (7.8.2018), 1-9, 12.2018
- Creator
-
Lee, Joshua L.
- Contributor
-
Sinnathurai, Premarani
Buchbinder, Rachelle
Hill, Catherine
Lassere, Marissa
March, Lyn
SpringerLink (Online service)
- DOI
-
10.1186/s13075-018-1669-x
- URN
-
urn:nbn:de:101:1-2018100722102159141737
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:30 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Lee, Joshua L.
- Sinnathurai, Premarani
- Buchbinder, Rachelle
- Hill, Catherine
- Lassere, Marissa
- March, Lyn
- SpringerLink (Online service)
Other Objects (12)
Biologics, cardiovascular effects and cancer
P11.24: Rheumatoid Arthritis and Cardiovascular Events
Editorial: Methods in cardiovascular biologics and regenerative medicine
Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study
Treatment persistence of biologics among patients with psoriatic arthritis
Factors associated with discontinuation of biologics in patients with inflammatory arthritis in remission: data from the BIOBADASER registry
Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review
Similar risk of cardiovascular events in idiopathic inflammatory myopathy and rheumatoid arthritis in the first 5 years after diagnosis
Correction: Factors associated with discontinuation of biologics in patients with inflammatory arthritis in remission: data from the BIOBADASER registry
Real-world retention rates of biologics in patients with rheumatoid arthritis
Intrauterine Exposure to Biologics in Inflammatory Autoimmune Diseases: A Systematic Review
Features and Outcomes of Microcrystalline Arthritis Treated by Biologics: A Retrospective Study
Biologics, cardiovascular effects and cancer
P11.24: Rheumatoid Arthritis and Cardiovascular Events
Editorial: Methods in cardiovascular biologics and regenerative medicine
Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study
Treatment persistence of biologics among patients with psoriatic arthritis
Factors associated with discontinuation of biologics in patients with inflammatory arthritis in remission: data from the BIOBADASER registry
Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review
Similar risk of cardiovascular events in idiopathic inflammatory myopathy and rheumatoid arthritis in the first 5 years after diagnosis
Correction: Factors associated with discontinuation of biologics in patients with inflammatory arthritis in remission: data from the BIOBADASER registry
Real-world retention rates of biologics in patients with rheumatoid arthritis
Intrauterine Exposure to Biologics in Inflammatory Autoimmune Diseases: A Systematic Review
Features and Outcomes of Microcrystalline Arthritis Treated by Biologics: A Retrospective Study
Biologics, cardiovascular effects and cancer
P11.24: Rheumatoid Arthritis and Cardiovascular Events
Editorial: Methods in cardiovascular biologics and regenerative medicine
Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study
Treatment persistence of biologics among patients with psoriatic arthritis
Factors associated with discontinuation of biologics in patients with inflammatory arthritis in remission: data from the BIOBADASER registry
Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review
Similar risk of cardiovascular events in idiopathic inflammatory myopathy and rheumatoid arthritis in the first 5 years after diagnosis
Correction: Factors associated with discontinuation of biologics in patients with inflammatory arthritis in remission: data from the BIOBADASER registry
Real-world retention rates of biologics in patients with rheumatoid arthritis
Intrauterine Exposure to Biologics in Inflammatory Autoimmune Diseases: A Systematic Review